Abstract |
A Phase II study of paclitaxel in patients with primary advanced or metastatic breast cancer was conducted by a cooperative study group consisting of 16 institutions in Japan. Paclitaxel at a dose of 210 mg/m2 was intravenously infused over 3 hours, along with premedication to prevent hypersensitivity reactions. The course was repeated at 21-day intervals. Of 62 eligible patients, 60 were evaluable for toxicity and 59 were evaluable for efficacy. Forty-five patients were previously treated with anthracyclines. Twenty-one of 59 patients (35.6%) had a major objective response including 2 CRs and 19 PRs (95% confidence interval, 23.6-49.1%). A response rate of 35.5% (CR1, PR10) was observed in 31 patients refractory to the anthracyclines containing prior metastatic chemotherapy. Median (range) time was 41 (6-100) days to onset of and median duration of response was 125 (36-305) days. Toxicities included leukopenia (grade 3, 4: 67%), anemia (grade 1-3: 80%), thrombocytopenia (grade 1: 8%), alopecia (grade 3: 43%), peripheral neuropathy (grade 1-3: 93%), arthralgia (59%), myalgia (46%), nausea and vomiting (40%), fever (33%), allergic reaction (grade 3: 2%) and hypotension (grade 3: 5%). All toxicities were tolerable and manageable. Paclitaxel intravenously infused over 3 hours demonstrated a significant antitumor activity for metastatic breast cancer. Furthermore, paclitaxel exhibited non-cross resistance to anthracycline. Paclitaxel administered as a convenient 3-hour infusion is effective for patients with metastatic breast cancer and has an acceptable toxicity profile.
|
Authors | Y Ito, N Horikoshi, T Watanabe, Y Sasaki, T Tominaga, T Okawa, T Tabei, Y Kuraishi, K Tamura, R Abe, M Kitajima, S Yamaguchi, T Kobayashi, H Koyama, K Orita, S Takashima, Y Nomura, M Ogawa |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 16
Issue 2
Pg. 183-90
( 1998)
ISSN: 0167-6997 [Print] United States |
PMID | 9848584
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Breast Neoplasms
(drug therapy, secondary)
- Drug Administration Schedule
- Female
- Humans
- Injections, Intravenous
- Middle Aged
- Neoplasm Staging
- Paclitaxel
(administration & dosage, adverse effects, therapeutic use)
|